Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential
anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous
human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the
phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of
CVM-1118 for patients with advanced neuroendocrine tumors.